Editor Profile

Thomas Glück, MD

Associate Editor

About the NEJM Journal Watch Infectious Diseases Board

Thomas Glück, MD, is Professor of Medicine at the University of Regensburg, Chief, Department of Internal Medicine, District Hospital Trostberg, and Chief, Infectious Diseases Consulting Service, District Hospitals, Traunstein and Trostberg, Bavaria, Germany. A member of the Bavarian infectious diseases specialty board, he received his specialty training in the U.S. His research interests include clinical sepsis, pathogenesis of sepsis, and infections in immunocompromised patients. Dr. Glück has been writing for NEJM Journal Watch Infectious Diseases since 2004.


Editorial boards

Consilium Infectiorum

Summaries by Thomas Glück

  • September 29, 2015

    Intestinal Niches for Resistant Pathogens

    1. Thomas Glück, MD

    Vancomycin-resistant enterococci and carbapenem-resistant Klebsiella pneumoniae grew independently of each other in the intestines of ampicillin-pretreated mice, but growth could be terminated by fecal transplantation.

  • September 29, 2015

    The Human Gut Microbiome — A Transporter of Antibiotic Resistance

    1. Thomas Glück, MD

    The abundance of genes encoding resistance to common antibiotics, including sulfonamides, trimethoprim, and β-lactams, increased by 6% after travel to India or Africa.

  • September 16, 2015

    Rapid Diagnosis of Infection in the Critically Ill

    1. Thomas Glück, MD

    Polymerase chain reaction/electrospray ionization–mass spectrometry provides pathogen identification in about 6 hours and appears to be significantly more sensitive than standard culture.

  • September 1, 2015

    Vitamin D Deficiency a Risk Factor for MRSA Infection?

    1. Thomas Glück, MD

    In a retrospective study involving Veterans Affairs patients in Atlanta, incidence of methicillin-resistant Staphylococcus aureus infections was nearly doubled among those with vitamin D deficiency.

  • August 18, 2015

    C. difficile–Associated Diarrhea — Very Costly

    1. Thomas Glück, MD

    A case-control study conducted in Germany estimated mean direct treatment costs of €18,463, €73,898 and €14,531 for single-episode, recurrent-disease, and control groups, respectively.

  • August 10, 2015

    Is MDR-TB Less Transmissible?

    1. Thomas Glück, MD

    Risk for developing active tuberculosis was approximately 50% lower among household contacts of patients with multidrug-resistant tuberculosis than among household contacts of those with drug-susceptible disease.